Drug discovery and development in TB

Fighting the global tuberculosis (TB) epidemic calls for the development of new, more potent antibiotics that inhibit Mycobacterium tuberculosis' critical proteins. The main goal of drug design and discovery is to identify a chemical that can specifically target a specific cavity in a protein and prevent it from engaging in its enzymatic function. A variety of studies, including clinical trials, are subsequently performed on the substance in question to determine how well it works to combat the infection inside the host. Recently, as opposed to the tedious and time-consuming old methods of drug design, new strategies that involve computational and analytical methodologies have improved the odds of drug discovery.
A new generation of software that is utilized to create and optimize active compounds that can be used in chemotherapeutic research in the future to tackle global tuberculosis resistance has improved computational methodologies in drug creation.

 

    Related Conference of Drug discovery and development in TB

    April 14-15, 2025

    15th European Epidemiology and Public Health Congress

    Budapest, Hungary
    June 02-03, 2025

    14th World Congress on Rare Diseases and Orphan Drugs

    Amsterdam, Netherlands
    June 02-03, 2025

    17th Euro-Global Conference on Infectious Diseases

    Amsterdam, Netherlands
    August 28-29, 2025

    8th Pathology and Infectious Disease Conference

    London, UK
    September 22-23, 2025

    11th International Conference on Infectious and Rare Diseases

    Vancouver, Canada
    December 11-12, 2025

    8th Annual Congress on Bacterial, Viral and Infectious Diseases

    Prague, Czech Republic

    Drug discovery and development in TB Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in